PubHawk
Am J Clin Dermatol September 2022 PMID 35854102

Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas.

Amanda Krenitsky, Skylar Klager, Leigh Hatch, Carlos Sarriera-Lazaro, Pei Ling Chen, Lucia Seminario-Vidal

Full text PDF Download social card

Mentions

6
Peak: 2 in Jul 2022
across 3 sources since Jul 2022

Extended reach

4,593
potential audience

Total likes

88

Video views

3,605

Mentions per month

Jul 2022 – May 2024

Where it's discussed

  • X / Twitter2 posts
  • YouTube2 videos
  • Facebook2 posts

AI synopsis

What people are saying

The discussions highlight key aspects of the article, such as the features of pCBCL subtypes and novel treatments like immune checkpoint inhibitors and CAR T-cell therapy. The tone is clinical and informative, emphasizing advancements and diagnostic challenges, which reflects a moderate level of interest and engagement with the topic's importance.

AgreementNeither agree nor disagree

The discussions acknowledge the importance of the article without showing strong approval or disagreement, reflecting a neutral stance.

InterestModerate interest

Posts express moderate curiosity, particularly focusing on new and innovative therapies, indicating some level of engagement.

EngagementModerate engagement

Comments reference specific content, such as features of pCBCL subtypes and therapeutic advances, suggesting active participation.

ImpactModerate impact

The focus on recent developments hints at a perceived significance, though the overall tone remains more informational than transformational.

Abstract in brief

  • Primary cutaneous B-cell lymphomas (pCBCLs) are rare diseases, making up about 25-30% of all primary cutaneous lymphomas, with an incidence of 0.51 cases per 100,000 people annually.
  • There are three main subtypes of pCBCL: primary cutaneous marginal zone lymphoma, follicle center lymphoma, and diffuse large B-cell lymphoma leg type, each with diverse clinical features that complicate diagnosis and treatment.
  • Recent advances include new therapies such as monoclonal antibodies, immune checkpoint inhibitors, and CAR T-cell therapy, which show promise as potential first-line treatments by targeting the disease’s underlying molecular mechanisms.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Paperbirds_Hematology
@PaperbirdsM · X

New article: Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas https://t.co/AlhtpbBBKE #DLBCL #lymsm #hematology https://t.co/QShdvpTUEK

Jul 20, 2022 · 1 like · 912 followers View post →
Kathy Fraser
@AmJClinDerma · X

Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas Amanda Krenitsky et al. discuss the features of the most common pCBCL subtypes with a focus on current and innovative therapeutic developments in their management. https://t.co/ypm3ce8NXH https://t.co/w0yky99gux

Jul 20, 2022 · 1 like · 77 followers View post →

All mentions

Kathy Fraser
@AmJClinDerma · X

Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas Amanda Krenitsky et al. discuss the features of the most common pCBCL subtypes with a focus on current and innovative therapeutic developments in their management. https://t.co/ypm3ce8NXH https://t.co/w0yky99gux

Jul 20, 2022 · 1 like · 77 followers View post →
Paperbirds_Hematology
@PaperbirdsM · X

New article: Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas https://t.co/AlhtpbBBKE #DLBCL #lymsm #hematology https://t.co/QShdvpTUEK

Jul 20, 2022 · 1 like · 912 followers View post →